Tilray Brands, Inc. (TLRY) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-05-31..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-05-31..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-05-31..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-05-31..
Free cash flow
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-69.14M | Cash generated by operating activities. Period ending 2026-05-31. |
| Operating cash flow / net income · 12 months | 0.57× | Operating cash flow / net income. Period ending 2026-05-31. $-69.14M ÷ $-121.40M ≈ 0.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -69.14M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 915.45M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -121.40M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | (m) | (m) | $-69.14M | (m) | (m) | $915.45M | (m) | $-121.40M | (m) | (m) | (m) | 0.57× |
| 2026-02-28 | (m) | (m) | $-44.63M | (m) | (m) | $858.27M | (m) | $-1.34B | (m) | (m) | (m) | 0.03× |
| 2025-11-30 | (m) | (m) | $-28.45M | (m) | (m) | $837.32M | (m) | $-2.11B | (m) | (m) | (m) | 0.01× |
| 2025-08-31 | (m) | (m) | $-60.63M | (m) | (m) | $830.77M | (m) | $-2.15B | (m) | (m) | (m) | 0.03× |
| 2025-05-31 | (m) | (m) | $-94.60M | (m) | (m) | $821.31M | (m) | $-2.19B | (m) | (m) | (m) | 0.04× |
| 2025-02-28 | (m) | (m) | $-51.09M | (m) | (m) | $826.66M | (m) | $-945.69M | (m) | (m) | (m) | 0.05× |
| 2024-11-30 | (m) | (m) | $-60.69M | (m) | (m) | $829.22M | (m) | $-248.96M | (m) | (m) | (m) | 0.24× |
| 2024-08-31 | (m) | (m) | $-50.37M | (m) | (m) | $812.04M | (m) | $-212.62M | (m) | (m) | (m) | 0.24× |
| 2024-05-31 | (m) | (m) | $-30.91M | (m) | (m) | $788.94M | (m) | $-244.98M | (m) | (m) | (m) | 0.13× |
| 2024-02-29 | (m) | (m) | $-18.01M | (m) | (m) | $743.25M | (m) | $-351.95M | (m) | (m) | (m) | 0.05× |
| 2023-11-30 | (m) | (m) | $-21.29M | (m) | (m) | $700.50M | (m) | $-1.43B | (m) | (m) | (m) | 0.01× |
| 2023-08-31 | (m) | (m) | $38.33M | (m) | (m) | $650.86M | (m) | $-1.45B | (m) | (m) | (m) | -0.03× |
| 2023-05-31 | (m) | (m) | $7.91M | (m) | (m) | $627.12M | (m) | $-1.45B | (m) | (m) | (m) | -0.01× |
| 2023-02-28 | (m) | (m) | $-56.22M | (m) | (m) | $596.26M | (m) | $-1.79B | (m) | (m) | (m) | 0.03× |
| 2022-11-30 | (m) | (m) | $-83.97M | (m) | (m) | $602.54M | (m) | $-577.90M | (m) | (m) | (m) | 0.15× |
| 2022-08-31 | (m) | (m) | $-130.30M | (m) | (m) | $613.56M | (m) | $-508.63M | (m) | (m) | (m) | 0.26× |
| 2022-05-31 | (m) | (m) | $-177.26M | (m) | (m) | $628.37M | (m) | $-476.80M | (m) | (m) | (m) | 0.37× |
| 2022-02-28 | (m) | (m) | $-148.49M | (m) | (m) | $617.28M | (m) | $41.68M | (m) | (m) | (m) | -3.56× |
| 2021-11-30 | (m) | (m) | $-101.40M | (m) | (m) | $589.31M | (m) | $-275.03M | (m) | (m) | (m) | 0.37× |
| 2021-08-31 | (m) | (m) | $-81.84M | (m) | (m) | $563.62M | (m) | $-374.73M | (m) | (m) | (m) | 0.22× |
| 2021-05-31 | (m) | (m) | $-44.72M | (m) | (m) | $513.09M | (m) | $-367.42M | (m) | (m) | (m) | 0.12× |
| 2021-03-31 | $-117.15M | (m) | $-88.33M | $28.82M | (m) | (m) | (m) | $-427.90M | (m) | (m) | (m) | 0.21× |
| 2021-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-494.87M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-174.00M | (m) | $-129.35M | $44.64M | (m) | (m) | (m) | $-271.07M | (m) | (m) | (m) | 0.48× |
| 2020-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-232.35M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-257.98M | (m) | $-195.30M | $62.69M | (m) | (m) | (m) | $-487.27M | (m) | (m) | (m) | 0.40× |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-138.45M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-313.31M | (m) | $-238.34M | $74.97M | (m) | (m) | (m) | $-521.31M | (m) | (m) | (m) | 0.46× |
| 2020-05-31 | (m) | (m) | $-100.63M | (m) | (m) | $405.33M | (m) | $-102.54M | (m) | (m) | (m) | 0.98× |
| 2020-03-31 | $-370.27M | (m) | $-287.25M | $83.01M | (m) | (m) | (m) | $-475.92M | (m) | (m) | (m) | 0.60× |
| 2019-12-31 | $-331.81M | (m) | $-258.06M | $73.74M | (m) | (m) | (m) | $-321.17M | (m) | (m) | (m) | 0.80× |
| 2019-09-30 | $-249.61M | (m) | $-187.06M | $62.54M | (m) | (m) | (m) | $-132.04M | (m) | (m) | (m) | 1.42× |
| 2019-06-30 | $-201.79M | (m) | $-153.57M | $48.22M | (m) | (m) | (m) | $-115.06M | (m) | (m) | (m) | 1.33× |
| 2019-05-31 | (m) | (m) | $-42.05M | (m) | (m) | $179.30M | (m) | $-25.04M | (m) | (m) | (m) | 1.68× |
| 2019-03-31 | $-115.72M | (m) | $-69.36M | $46.36M | (m) | (m) | (m) | $-92.84M | (m) | (m) | (m) | 0.75× |
| 2018-12-31 | $-96.45M | (m) | $-46.25M | $50.20M | (m) | (m) | (m) | $-67.72M | (m) | (m) | (m) | 0.68× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-12.31M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-16.91M | (m) | $-6.00M | $10.91M | (m) | (m) | (m) | $-7.81M | (m) | (m) | (m) | 0.77× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-3.81M | (m) | $-3.32M | $488.00K | (m) | (m) | (m) | $-7.88M | (m) | (m) | (m) | 0.42× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |